La bioventure RudaCure s'associe aux leaders des médicaments vétérinaires Onhil et Onhil Pet pour le développement de médicaments pour animaux

RudaCure Inc. (PDG Yongho Kim), une entreprise bioventure spécialisée dans les maladies des troubles sensoriels, a signé a complet MOU for développement de médicaments vétérinaires, production, and sales with Onhil Co., Ltd. (CEOs Kim Do-hyung and Yoo Jeong-woo) and Onhil Pet Co., Ltd. (CEOs Ko Hyun-gyu and Ryu Tae-seong), companies specializing in pharmaceutique vétérinaire essais cliniques and distribution.

Under this accord, the three companies will initially co-develop treatments for companion animals, notamment ear inflammation treatments, sécheresse oculaire and traitement des lésions cornéenness, and dermatological formulations.

RudaCure Inc., which holds développement de médicaments know-how and patents, will be responsible for développement de médicaments, while Onhil Co., Ltd. and Onhil Pet Co., Ltd. will handle vétérinaire essais cliniques, production, and sales.

RudaCure Inc. already has licence experience with traitement de la sécheresse oculaires and traitement des lésions cornéenness in 2021 and 2023, and is actuellement also developing a best-in-class powerful analgésique non narcotique. L'entreprise is also actively conducting research on psoriasis and atopic dermatitis, and has récemment been selected for the 2023 K-Bio Health Regional Center Support Program a annoncé by Incheon Technopark, receiving support for prototype development, patents and certifications, and essais cliniques. De plus, l'entreprise a été sélectionnée pour KOTRA's foreign attraction d'investissements programme de soutien and plans to actively pursue overseas attraction d'investissements activities.

Onhil Co., Ltd. is a companion animal healthcare plateforme company sur la base de vétérinaire medicine under the vision of "One health. One happiness." L'entreprise is already supplying "DuraHeart SR-3," the world's first 3-month long-acting heartworm vaccine developed with a national patent, to animal hospitals. À l'avenir, l'entreprise prévoit de continuer bringing good vétérinaire medicine-based products to market and grow into a company that contributes more to companion animal health.

Through the MOU among three companies with strong technology and sales capabilities, it is expected that specialized développement de médicaments vétérinaires in the expanding companion animal pharmaceutique market will contribute to a healthy and happy coexistence between companion animals and humans.